HEMOSTIMULATING PROPERTIES OF THE CONJUGATES OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR WITH ALENDRONIC ACID

被引:0
|
作者
Shimina, G. G. [1 ]
Bateneva, A. V. [1 ]
Tsyplenkova, E. S. [1 ]
Gamaley, S. G. [1 ]
Esina, T. I. [1 ]
Volosnikova, E. A. [1 ]
Danilenko, E. D. [1 ]
机构
[1] Inst Med Biotechnol State Res Ctr Virol & Biotechn, Fed Serv Surveillance Consumer Rights Protect & Hu, Khimzavodskaya St, Berdsk 633004, Russia
来源
PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA | 2022年 / 10卷 / 05期
关键词
recombinant human granulocyte-macrophage colony-stimulating factor; alendronic acid; conjugate; hemostimulating activity; accumulation in bone tissue and bone marrow; GM-CSF; ANTITUMOR-ACTIVITY; BONE; BISPHOSPHONATE; THERAPY; METHOTREXATE; DISPOSITION; DELIVERY;
D O I
10.19163/2307-9266-2022-10-5-472-482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the work is to evaluate the hemostimulating activity of recombinant human granulocyte-macrophage colony -stimulating factor (rhGM-CSF) conjugates with alendronic acid (ALN) in the model of cytostatic myelosuppression and the dynamics of rhGM-CSF accumulation as a part of the conjugate in the bone tissue and bone marrow of mice.Materials and methods. The conjugates obtained by a solid-phase synthesis using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide or periodate oxidation, were used. A hemostimulating activity was evaluated in a model of a cytostatic myelosuppression induced by the administration of cyclophosphamide to CBA/Calac mice. RhGM-CSF preparations were injected subcutaneously for 4-5 days at the dose of 90 mu g/kg. After the injections cycle had been completed, the total leukocyte and segmented neutrophil counts were carried out in the blood samples, and the total karyocyte count was carried out in the bone marrow samples. The tissue distribution of rhGM-CSF preparations was assessed in outbred CD-1 mice after a single intravenous administration at the effective dose. The content of rhGM-CSF in blood, femoral tissue and bone marrow was determined by enzyme immunoassay.Results. RhGM-CSF conjugates with ALN have been shown to retain the ability of the original protein to increase the number of leukocytes, segmented blood neutrophils, and bone marrow karyocytes under the action of conjugates. The stimulation of the neutrophil production used to be observed at earlier times than in the case of rhGM-CSF. The increase in the total number of bone marrow cells after the introduction of all three conjugates was more pronounced compared to the original protein (by 34%). The increased hemostimulatory effect of the AEG conjugate was accompanied by a more intense accumulation of rhGM-CSF in the bone tissue and bone marrow of mice. The rhGM-CSF introduced into the conjugate was detected in the bone tissue for 24 h and it circulated in the bloodstream for a longer time compared to the original protein.Conclusion. The data obtained make it possible to conclude that further work on the development of effective hemostimulating drugs based on rhGM-CSF conjugates with ALN, is promising.
引用
收藏
页码:472 / 482
页数:11
相关论文
共 50 条
  • [1] Granulocyte-macrophage colony-stimulating factor and the immune system
    Tarr, PE
    MEDICAL ONCOLOGY, 1996, 13 (03): : 133 - 140
  • [2] Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo
    Aman, MJ
    Stockdreher, K
    Thews, A
    Kienast, K
    Aulitzky, WE
    Farber, L
    Haus, U
    Koci, B
    Huber, C
    Peschel, C
    ANNALS OF HEMATOLOGY, 1996, 73 (05) : 231 - 238
  • [3] Deletion mutants of human granulocyte-macrophage colony-stimulating factor
    Petrovskaya, LE
    Kryukova, EA
    Kayushin, AL
    Rodina, AV
    Moskaleva, EY
    Korobko, VG
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2002, 28 (05) : 397 - 403
  • [5] Deletion Mutants of Human Granulocyte-Macrophage Colony-Stimulating Factor
    L. E. Petrovskaya
    E. A. Kryukova
    A. L. Kayushin
    A. V. Rodina
    E. Yu. Moskaleva
    V. G. Korobko
    Russian Journal of Bioorganic Chemistry, 2002, 28 : 397 - 403
  • [6] New clinical applications of granulocyte-macrophage colony-stimulating factor
    Masucci, G
    MEDICAL ONCOLOGY, 1996, 13 (03): : 149 - 154
  • [7] Emerging paradigms in granulocyte-macrophage colony-stimulating factor signaling
    GomezCambronero, J
    Veatch, C
    LIFE SCIENCES, 1996, 59 (25-26) : 2099 - 2111
  • [9] Granulocyte-macrophage colony-stimulating factor for newly diagnosed glioblastoma
    Cao, Caineng
    Wang, Le
    Jiang, Feng
    Jin, Qifeng
    Jin, Ting
    Huang, Shuang
    Hu, Qiaoying
    Chen, Yuanyuan
    Piao, Yongfeng
    Hua, Yonghong
    Feng, Xinglai
    Zhou, Yi
    Chen, Xiaozhong
    NEOPLASIA, 2025, 63
  • [10] Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor
    Sasaki, M
    Tsuneyama, K
    Ishikawa, A
    Nakanuma, Y
    HUMAN PATHOLOGY, 2003, 34 (12) : 1337 - 1344